Amyris — Investor Presentation (April 2017)
13 slides from Amyris's investor presentation, Apr 18, 2017
Slide 1: Innovative Science for a Healthier Planet: Corporate Overview
Copyright © 2017 Amyris, Inc. All rights reserved. 232/151/55 0/90/132 145/145/149 178/187/30 185/52/75 105/109/17 117/76/12 Innovative Science for a Healthier Planet Corporate Overview April 2017
Slide 2: Forward-Looking Statements
Copyright © 2017 Amyris, Inc. All rights reserved. 232/151/55 0/90/132 145/145/149 178/187/30 185/52/75 105/109/17 117/76/12 FORWARD - LOOKING STATEMENTS This presentation contains forward - looking statements, and any statements other than statements of historical fact could be deemed to be forward
Slide 3: Amyris at a Glance for 2016
Copyright © 2017 Amyris, Inc. All rights reserved. 232/151/55 0/90/132 145/145/149 178/187/30 185/52/75 105/109/17 117/76/12 Amyris at a Glance for 2016 Brands with “Amyris inside” over 500 Consumers touched by Amyris 200M Commercial products 15 Revenue producing partners 14 c.a. $50M Avg. collabora
Slide 4: Our Mission and Our Promise
Copyright © 2017 Amyris, Inc. All rights reserved. 232/151/55 0/90/132 145/145/149 178/187/30 185/52/75 105/109/17 117/76/12 Our Mission – Enable a healthier planet, one molecule at a time Our Promise – Lower cost, better performing ingredients that enable our Partners to disrupt their fastest growi
Slide 5: Over 90% of product revenue growth supported by world class partners
Copyright © 2017 Amyris, Inc. All rights reserved. 232/151/55 0/90/132 145/145/149 178/187/30 185/52/75 105/109/17 117/76/12 Over 90% of our product revenue growth supported by World Class partners and existing agreements Health & Nutrition • Pharma • Nutraceuticals • Food Ingredients Personal Care
Slide 6: Growth driven by strong fundamental trends
Copyright © 2017 Amyris, Inc. All rights reserved. 232/151/55 0/90/132 145/145/149 178/187/30 185/52/75 105/109/17 117/76/12 Growth driven by strong fundamental trends Health & Wellness Global Shifts Market Volatility Health & Nutrition Personal Care Performance Materials Food consumption Healthcare
Slide 7: Integrated technology platform provides access to over $200B of available market
Copyright © 2017 Amyris, Inc. All rights reserved. 232/151/55 0/90/132 145/145/149 178/187/30 185/52/75 105/109/17 117/76/12 Our integrated technology platform provides access to over $200B of available market
Slide 8: We Deliver Lower CapEx, Disruptive Growth & Better Chemistry
Copyright © 2017 Amyris, Inc. All rights reserved. 232/151/55 0/90/132 145/145/149 178/187/30 185/52/75 105/109/17 117/76/12 We Deliver Lower CapEx, Disruptive Growth & Better Chemistry Synthetic Chemistry + + + Industrial Biotech Amyris has industrialized biotechnology - delivering predictable scal
Slide 9: Distinctive and Advantaged Business Model
Copyright © 2017 Amyris, Inc. All rights reserved. 232/151/55 0/90/132 145/145/149 178/187/30 185/52/75 105/109/17 117/76/12 Distinctive and Advantaged Business Model Removes Product and Market Risk while Funding Development 1 2 3 4 Target Develop Supply Profit split Upfront funding Milestone paymen
Slide 10: Value Share Business Model enables sector leading growth
Copyright © 2017 Amyris, Inc. All rights reserved. 232/151/55 0/90/132 145/145/149 178/187/30 185/52/75 105/109/17 117/76/12 Value Share Business Model enables sector leading growth Collaboration Revenue Product Margin Value Share Margin Collaboration Revenue Product Margin Value Share Gross Margin
Slide 11: Historical Actual and Targeted Revenue Opportunity
Copyright © 2017 Amyris, Inc. All rights reserved. 232/151/55 0/90/132 145/145/149 178/187/30 185/52/75 105/109/17 117/76/12 Historical Actual and Targeted Revenue Opportunity* 2015 2016 2017 2018 2019 Collaboration revenue Personal Care Performance Material Health & Nutrition *Targeted revenue oppo
Slide 12: Leading Shareholders and Board of Directors
Copyright © 2017 Amyris, Inc. All rights reserved. 232/151/55 0/90/132 145/145/149 178/187/30 185/52/75 105/109/17 117/76/12 BIOLDING INVESTMENTS All others Leading Shareholders and Board of Directors Geoff Duyk John Melo Patrick Yang Former Global Head, Technical Operations Roche/Genentech Christop
Slide 13: Amyris Investment Highlights
Copyright © 2017 Amyris, Inc. All rights reserved. 232/151/55 0/90/132 145/145/149 178/187/30 185/52/75 105/109/17 117/76/12 Leading technology platform in sector , IP protected, broad application to multiple, high - growth industries Collaboration portfolio and pipeline with product sales potential